Research University conducts HIV treatment adherence dose determination trial
Photo by Joshua Coleman
University of Connecticut with collaboration from the National Institute of Mental Health (NIMH) is commencing recruitment for the clinical trial of HIV treatment adherence dose determination.
The proposed research will conduct the first dose-determination trial to find the optimal number of behavioral counseling sessions (dose) needed to achieve and sustain optimal HIV treatment adherence. The results of this study will determine how much intervention is needed for whom and at what cost to guide health policy and implementation of behavioral interventions designed to improve durable viral suppression.
This research will conduct the first ever dose-determination trial of a behavioral intervention to improve engagement in HIV care, antiretroviral therapy (ART) adherence and HIV viral suppression.
A new clinical trial is recruiting patients in the following locations: Connecticut and Georgia in United States.
The actual study start date is September 1, 2020.
The indicators for inclusion are
- confirmed HIV positive;
- confirmed prescribed antiretroviral therapy;
- confirmed non-adherent to anti-retroviral therapy.
The University of Connecticut (UConn) is a public research university in Storrs, Connecticut. The university is classified among "R1: Doctoral Universities – Very high research activity".
